Interferon (IFN)–specific autoantibodies have been implicated in severe coronavirus disease
2019 (COVID-19) and have been proposed as a potential driver of the persistent symptoms …

Long COVID (LC) is an emerging global health concern. The underlying mechanism and
pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 …

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some
patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe …

Purpose Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1%
of individuals under the age of 60 in the general population, with the prevalence increasing …

Background Neutralizing anti-interferon (IFN)-γ autoantibodies are linked to adult-onset
immunodeficiency and opportunistic infections. Methods To explore whether anti-IFN-γ …

To the Editor, Bastard et al. reported that autoantibodies neutralizing type I interferons (IFN)
s are found in at least 18% of deceased COVID-19 patients [1]. They also showed that the …

Autoantibodies (AABs) neutralizing type I interferons (IFN) underlie about 15% of cases of
critical coronavirus disease 2019 (COVID-19) pneumonia. The impact of autoimmunity …

Objectives Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …

Binding levels and neutralization activity of anti–type 1 interferon autoantibodies peaked
during acute coronavirus disease 2019 and markedly decreased thereafter. Most patients …

Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune
mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest …